IDH2 and astrocytoma (excluding glioblastoma): IDH wildtype (wt) astrocytomas, despite being considered as WHO grade II or III based on histologic criteria alone (e.g., no microvascular proliferation or necrosis), have poorer overall survival (OS) when compared with IDH mutated astrocytomas WHO grade II or III [1–4].